Effectiveness and safety of docetaxel combined with cisplatin in the second-line treatment of advanced non-small cell lung cancer in older adult patients / 中国基层医药

ABSTRACT

Objective:To investigate the effectiveness and safety of docetaxel combined with cisplatin in the second-line treatment of advanced non-small cell lung cancer in older adult patients.Methods:120 older adult patients with advanced non-small cell lung cancer who received second-line treatment in Jiaozhou People's Hospital from January 2017 to December 2019 were included in this study. They were randomly assigned to undergo treatment with docetaxel (control group, n = 60) or docetaxel + cisplatin (observation group, n = 60). Clinical efficacy and complications were compared between the two groups. Results:After chemotherapy, short-term total response rate was significantly higher in the observation group than in the control group [70.00% (42/60) vs. 33.33% (20/60), χ2 = 16.15, P < 0.05]. Serum levels of carcinoembryonic antigen, carbohydrate antigen 125, cytokeratin 19-fragment CYFRA21-1 were (22.57 ± 3.22) μg/L, (48.61 ± 5.42) U/mL, (10.61 ± 1.64) μg/L, respectively in the observation group, which were significantly lower than those in the control group [(35.52 ± 4.46) μg/L, (69.64 ± 7.75) U/mL, (14.26 ± 1.95) μg/L, t = 18.23, 17.22, 11.09, all P < 0.001]. The percentages of CD 3+ and CD 4+ cells were (78.31 ± 8.09)% and (48.63 ± 5.74)%, respectively in the observation group, which were significantly higher than those in the control group [(69.58 ± 7.26)%, (39.82 ± 4.25)%, t = -6.22, -9.55, both P < 0.001]. The percentage of CD 8+ was significantly lower in the observation group than in the control group [(22.64 ± 3.82)% vs. (26.77 ± 4.01)%, t = 5.77, P < 0.001). The 1-year survival was significantly higher in the observation group than in the control group ( χ2 = 4.05, P < 0.05). There was no significant difference in the incidence of adverse reactions during chemotherapy between the two groups ( P > 0.05). Conclusion:Docetaxel combined with cisplatin is highly effective on advanced non-small cell lung cancer in older adult patients. The combined therapy can decrease serum tumor marker levels, improve immune function, and increase 1-year survival rate. It is safe and provides reliable efficacy and thereby is worthy of clinical promotion.